- call +1-201-465-4211
- email sales@mrinsights.biz
Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point mutations within TTR allele, wild-type ATTR is caused by the misfolding of Wild-Type TTR. Major prevalence of Hereditary ATTR is observed in the 7MM, and this type has been further sub-classified into Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis Cardiomyopathy (FAC).
Scope of the Report:
This report studies the Transthyretin Amyloidosis (ATTR) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Transthyretin Amyloidosis (ATTR) market by product type and applications/end industries.
United States accounts for highest ATTR Amyloidosis Cases, followed by EU5 (Italy, France, Spain, Germany, UK) and Japan.
The global Transthyretin Amyloidosis (ATTR) market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Transthyretin Amyloidosis (ATTR).
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Pfizer
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Hereditary ATTR (HATTR)
Wild-Type (WT) ATTR
Market Segment by Applications, can be divided into
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Transthyretin Amyloidosis (ATTR) Market Overview
1.1 Product Overview and Scope of Transthyretin Amyloidosis (ATTR)
1.2 Classification of Transthyretin Amyloidosis (ATTR) by Types
1.2.1 Global Transthyretin Amyloidosis (ATTR) Revenue Comparison by Types (2017-2023)
1.2.2 Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Types in 2017
1.2.3 Hereditary ATTR (HATTR)
1.2.4 Wild-Type (WT) ATTR
1.3 Global Transthyretin Amyloidosis (ATTR) Market by Application
1.3.1 Global Transthyretin Amyloidosis (ATTR) Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.4 Global Transthyretin Amyloidosis (ATTR) Market by Regions
1.4.1 Global Transthyretin Amyloidosis (ATTR) Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Transthyretin Amyloidosis (ATTR) Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Transthyretin Amyloidosis (ATTR) Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Transthyretin Amyloidosis (ATTR) Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Transthyretin Amyloidosis (ATTR) Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Transthyretin Amyloidosis (ATTR) Status and Prospect (2013-2023)
1.5 Global Market Size of Transthyretin Amyloidosis (ATTR) (2013-2023)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Transthyretin Amyloidosis (ATTR) Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2016-2017)
2.2 Alnylam Pharmaceuticals
2.2.1 Business Overview
2.2.2 Transthyretin Amyloidosis (ATTR) Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2016-2017)
2.3 Ionis Pharmaceuticals
2.3.1 Business Overview
2.3.2 Transthyretin Amyloidosis (ATTR) Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2016-2017)
2.4 Corino Therapeutics
2.4.1 Business Overview
2.4.2 Transthyretin Amyloidosis (ATTR) Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2016-2017)
2.5 Proclara Bioscience
2.5.1 Business Overview
2.5.2 Transthyretin Amyloidosis (ATTR) Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2016-2017)
2.6 Arcturus Therapeutics
2.6.1 Business Overview
2.6.2 Transthyretin Amyloidosis (ATTR) Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2016-2017)
3 Global Transthyretin Amyloidosis (ATTR) Market Competition, by Players
3.1 Global Transthyretin Amyloidosis (ATTR) Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Transthyretin Amyloidosis (ATTR) Players Market Share
3.2.2 Top 10 Transthyretin Amyloidosis (ATTR) Players Market Share
3.3 Market Competition Trend
4 Global Transthyretin Amyloidosis (ATTR) Market Size by Regions
4.1 Global Transthyretin Amyloidosis (ATTR) Revenue and Market Share by Regions
4.2 North America Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
4.3 Europe Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
4.5 South America Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
5 North America Transthyretin Amyloidosis (ATTR) Revenue by Countries
5.1 North America Transthyretin Amyloidosis (ATTR) Revenue by Countries (2013-2018)
5.2 USA Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
5.3 Canada Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
5.4 Mexico Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
6 Europe Transthyretin Amyloidosis (ATTR) Revenue by Countries
6.1 Europe Transthyretin Amyloidosis (ATTR) Revenue by Countries (2013-2018)
6.2 Germany Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
6.3 UK Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
6.4 France Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
6.5 Russia Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
6.6 Italy Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue by Countries
7.1 Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue by Countries (2013-2018)
7.2 China Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
7.3 Japan Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
7.4 Korea Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
7.5 India Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
8 South America Transthyretin Amyloidosis (ATTR) Revenue by Countries
8.1 South America Transthyretin Amyloidosis (ATTR) Revenue by Countries (2013-2018)
8.2 Brazil Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
8.3 Argentina Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
8.4 Colombia Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Transthyretin Amyloidosis (ATTR) by Countries
9.1 Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue by Countries (2013-2018)
9.2 Saudi Arabia Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
9.3 UAE Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
9.4 Egypt Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
9.5 Nigeria Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
9.6 South Africa Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2013-2018)
10 Global Transthyretin Amyloidosis (ATTR) Market Segment by Type
10.1 Global Transthyretin Amyloidosis (ATTR) Revenue and Market Share by Type (2013-2018)
10.2 Global Transthyretin Amyloidosis (ATTR) Market Forecast by Type (2018-2023)
10.3 Hereditary ATTR (HATTR) Revenue Growth Rate (2013-2023)
10.4 Wild-Type (WT) ATTR Revenue Growth Rate (2013-2023)
11 Global Transthyretin Amyloidosis (ATTR) Market Segment by Application
11.1 Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Application (2013-2018)
11.2 Transthyretin Amyloidosis (ATTR) Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Ambulatory Surgical Centers Revenue Growth (2013-2018)
11.5 Diagnostic Centers Revenue Growth (2013-2018)
12 Global Transthyretin Amyloidosis (ATTR) Market Size Forecast (2018-2023)
12.1 Global Transthyretin Amyloidosis (ATTR) Market Size Forecast (2018-2023)
12.2 Global Transthyretin Amyloidosis (ATTR) Market Forecast by Regions (2018-2023)
12.3 North America Transthyretin Amyloidosis (ATTR) Revenue Market Forecast (2018-2023)
12.4 Europe Transthyretin Amyloidosis (ATTR) Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue Market Forecast (2018-2023)
12.6 South America Transthyretin Amyloidosis (ATTR) Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Transthyretin Amyloidosis (ATTR) Picture
Table Product Specifications of Transthyretin Amyloidosis (ATTR)
Table Global Transthyretin Amyloidosis (ATTR) and Revenue (
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
